Feature Channels: Vaccines

• share
• favorite_border

As part of a recently launched international phase 3 clinical trial, Montefiore Health System and Albert Einstein College of Medicine are investigating whether the Merck antiviral pill, molnupiravir, now approved in Britain for treating COVID-19, can prevent COVID-19 in unvaccinated individuals living with people who have contracted the disease. Montefiore-Einstein is the first and only New York State site for the trial and was selected due to its diverse patient population and expertise in clinical trials of COVID-19 and other infectious diseases.

• share
• favorite_border

Cedars-Sinai's COVID-19 vaccine drive-thru is now open to children 5 and older, following the U.S. Food and Drug Administration (FDA) authorization and Centers for Disease Control and Prevention (CDC) recommendation that the Pfizer-BioNTech vaccine is safe and effective in children.

• share
• favorite_border

CRI will bestow the 2021 William B. Coley Award for Distinguished Research in Basic Immunology on four mRNA vaccine scientists followed by roundtable on origin and future application to cancer treatment.

• share
• favorite_border

Rush psychologist offers help handling some tricky situations that may come up this holiday season

• share
• favorite_border

Joanna Drowos, D.O., M.P.H., M.B.A., FAU Schmidt College of Medicine, provides answers to some of the most frequently asked questions regarding the COVID-19 boosters and vaccines for children ages 5 to 11.

• share
• favorite_border

With two viruses threatening to make older adults sick this winter, a new poll shows most people over 50 have gotten protected by vaccines against both influenza and coronavirus, or plan to. And a majority of those who have gotten the COVID-19 vaccine plan to get an additional dose. But the poll also reveals major differences in vaccine attitudes between older adults, including those of different political leanings.

• share
• favorite_border

SEATTLE — Nov. 2, 2021 — Below are summaries of recent Fred Hutch research findings and other news.

• share
• favorite_border

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that people with chronic inflammatory diseases, such as rheumatoid arthritis (RA), who take immunosuppressive therapy appear to have an impaired immunity response to SARS-CoV-2, the coronavirus that causes COVID-19, vaccines. Patients currently on glucocorticoids or B-cell depleting therapy appear to have an even more severely impeded vaccine response.

• share
• favorite_border

In a newly published study, researchers at the University of Maryland School of Medicine have detected antibodies primarily made in response to infections in the mucous membranes — in such areas as the lungs, intestines, or vagina — in study participants with malaria.

• share
• favorite_border

• share
• favorite_border

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that in Alabama, one in 10 racial or ethnic minority patients with a rheumatic disease in a large rheumatology clinic said they were unlikely to get vaccinated against COVID-19.

• share
• favorite_border

The University of Delaware's Aditya Kunjapur has been awarded the 2021 American Institute of Chemical Engineers (AIChE) Langer Prize for Innovation and Entrepreneurial Excellence, a highly competitive award that comes with a stipend to pursue “blue sky” ideas.

• share
• favorite_border

Researchers at Cedars-Sinai found that patients with inflammatory bowel disease (IBD)─whose treatment can weaken the immune system─produced a strong antibody response to COVID-19 vaccination. The study findings have been published in the Annals of Internal Medicine.

• share
• favorite_border

Following FDA authorization of the COVID-19 vaccine for 5- to 11-year-olds, Together by St. Jude releases a free coloring book that educates children on COVID-19 vaccines.

• share
• favorite_border

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows patients using rituximab were able to produce antibodies against COVID-19 after receiving a third vaccine dose, even if there was no development of the antibody after the first two.

• share
• favorite_border

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that nearly 30% of patients with lupus in a multi-ethnic and multi-racial study had a low response to the new COVID-19 vaccines.